DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Empaveli is a drug marketed by Apellis Pharms and is included in one NDA. There are six patents protecting this drug.
This drug has one hundred and six patent family members in twenty countries.
The generic ingredient in EMPAVELI is pegcetacoplan. Additional details are available on the pegcetacoplan profile page.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be November 15, 2033. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for EMPAVELI
|DailyMed Link:||EMPAVELI at DailyMed|
DrugPatentWatch® Estimated Generic Entry Opportunity Date for EMPAVELI
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
|Country||Patent Number||Estimated Expiration|
|Hong Kong||1215445||⤷ Free Forever Trial|
|Spain||2526981||⤷ Free Forever Trial|
|Russian Federation||2653439||⤷ Free Forever Trial|
|Canada||2631443||⤷ Free Forever Trial|
|Canada||2833202||⤷ Free Forever Trial|
|Japan||2019206547||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|